- Home
- ZNTL vs NEWT Comparison
ZNTL vs NEWT Comparison
Compare ZNTL & NEWT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZNTL
- NEWT
- Stock Information
- Founded
- ZNTL 2014
- NEWT 1998
- Country
- ZNTL United States
- NEWT United States
- Employees
- ZNTL N/A
- NEWT N/A
- Industry
- ZNTL Biotechnology: Pharmaceutical Preparations
- NEWT Major Banks
- Sector
- ZNTL Health Care
- NEWT Finance
- Exchange
- ZNTL Nasdaq
- NEWT Nasdaq
- Market Cap
- ZNTL 105.8M
- NEWT 281.1M
- IPO Year
- ZNTL 2020
- NEWT N/A
- Fundamental
- Price
- ZNTL $1.19
- NEWT $11.88
- Analyst Decision
- ZNTL Buy
- NEWT Hold
- Analyst Count
- ZNTL 7
- NEWT 4
- Target Price
- ZNTL $8.60
- NEWT $14.00
- AVG Volume (30 Days)
- ZNTL 1.2M
- NEWT 189.4K
- Earning Date
- ZNTL 08-08-2025
- NEWT 07-28-2025
- Dividend Yield
- ZNTL N/A
- NEWT 6.38%
- EPS Growth
- ZNTL N/A
- NEWT 27.62
- EPS
- ZNTL N/A
- NEWT 1.92
- Revenue
- ZNTL $26,865,000.00
- NEWT $352,584,000.00
- Revenue This Year
- ZNTL N/A
- NEWT N/A
- Revenue Next Year
- ZNTL N/A
- NEWT $13.51
- P/E Ratio
- ZNTL N/A
- NEWT $6.19
- Revenue Growth
- ZNTL N/A
- NEWT 23.06
- 52 Week Low
- ZNTL $1.01
- NEWT $9.12
- 52 Week High
- ZNTL $5.44
- NEWT $15.49
- Technical
- Relative Strength Index (RSI)
- ZNTL 41.86
- NEWT 64.45
- Support Level
- ZNTL $1.13
- NEWT $11.21
- Resistance Level
- ZNTL $1.39
- NEWT $11.00
- Average True Range (ATR)
- ZNTL 0.11
- NEWT 0.30
- MACD
- ZNTL -0.02
- NEWT 0.15
- Stochastic Oscillator
- ZNTL 14.63
- NEWT 84.02
About ZNTL Zentalis Pharmaceuticals Inc.
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.
About NEWT NewtekOne Inc.
NewtekOne Inc is a financial holding company engaged in providing financial solutions to its Client Base. It is an internally managed non-diversified closed-end management investment company. It has four reportable segments Banking, Alternative Lending, Technology, NSBF, and Payments.